Quick Takeaways
- Slate Path Capital LP filed SCHEDULE 13G for Tvardi Therapeutics, Inc. Common stock, par value $0.001 per share (TVRD).
- Disclosed ownership: 7.5%.
- Date of event: 30 Jun 2025.
Slate Path Capital LP - 30 Jun 2025 SCHEDULE 13G Report for Tvardi Therapeutics, Inc. Common stock, par value $0.001 per share (TVRD)
- Filing Manager
- Slate Path Capital LP
- Reporting Manager
- Slate Path Capital LP
- Symbol
- TVRD
- Shares outstanding
- 9,388,240 shares
- Disclosed Ownership
- 704,118 shares
- Ownership
- 7.5%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Aug 2025, 16:15:31 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Slate Path Capital LP disclosed 7.5% ownership in Tvardi Therapeutics, Inc. Common stock, par value $0.001 per share (TVRD) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 16:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Slate Path Capital LP | 7.5% | 704,118 | 0 | 704,118 | /s/ Thomas Hansen | By: Jades GP, LLC, General Partner, By: Thomas Hansen, Chief Financial Officer and Chief Operating Officer | |
| David Greenspan | 7.5% | 704,118 | 0 | 704,118 | /s/ Jim Feeney | Jim Feeney, Attorney-In-Fact* |